相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1887
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A one-time triple combination of antiretroviral therapy, broadly neutralizing antibodies, and leronlimab cleared HIV in newborn macaques when given within three days of infection. - The study, published in Nature Microbiology, showed the regimen prevented viral reservoir seeding—an outcome no single therapy had achieved alone. - Researchers at Oregon Health & Science University say the approach could move directly into clinical trials, initially in newly exposed adults, before testing in newborns. - More than 120,000 infants acquire HIV worldwide each year, and a single-course intervention could dramatically reduce the burden of pediatric HIV in settings where lifelong treatment is difficult to maintain.
- Scientists at Oregon Health & Science University have mapped six major conformations of the acid-sensing ion channel ASIC1a in three-dimensional detail for the first time. - The study, published in Nature Structural & Molecular Biology, used cryo-electron microscopy to capture structural states by varying extracellular pH exposure. - Blocking ASIC1a has been shown to be neuroprotective, and the new structural blueprint could guide design of selective inhibitors to protect brain tissue during stroke. - Researchers in Australia are already exploring a spider venom-derived molecule targeting ASIC1a to improve outcomes in heart attack and stroke.
- Hillsboro Medical Center will shutter its 21-bed Center for Geriatric Psychiatry on September 4, eliminating one of only three acute inpatient psychiatric programs for older adults in Oregon. - Hospital leadership cites persistent staffing shortages, unsuccessful multi-year recruitment efforts, and consistently low patient volumes as the reasons for closure. - The Oregon Nurses Association has launched a public campaign opposing the closures, gathering over 1,570 signatures, and says 28 registered nurses are affected. - The remaining two geriatric psychiatry units in the state—Providence Milwaukie (19 beds) and Willamette Valley Medical Center (10 beds)—are frequently at or near capacity.
- The OHSU Board of Directors passed a resolution to significantly reduce primate experiments and transition the Oregon National Primate Research Center toward nonanimal, human-based research. - The resolution anticipates eventual removal of the center's federal designation as a National Primate Research Center, reflecting a broader federal shift away from animal testing. - More than 550 physicians separately called on HHS Secretary RFK Jr. to phase out primate experimentation across all seven National Primate Research Centers. - Modern human-based methods including organoids, microphysiological systems, and computational modeling are cited as more predictive of human outcomes than animal experiments.
- A Johns Hopkins University study published in the International Journal of Drug Policy finds Oregon's psilocybin program has evolved beyond strictly medical uses, with many clients citing general wellness and expanded consciousness as reasons for participation. - Researchers report a low number of adverse reactions but warn of safety concerns when individuals seek psilocybin for serious medical or psychiatric conditions, noting possible underreporting of negative events. - Most program clients come from high-income backgrounds and reside outside Oregon, raising questions about equitable access and the program's broad eligibility criteria codified in state law. - A separate federally funded OHSU study is underway to evaluate psilocybin safety in community settings, with findings on 72-hour post-treatment responses expected in July.
- Sanofi's protein-based Nuvaxovid COVID-19 vaccine showed significantly better tolerability than mNEXSPIKE mRNA vaccine in the COMPARE study, with fewer moderate-to-severe systemic and local symptoms. - The study found 61.3% of mNEXSPIKE recipients experienced moderate-to-severe systemic symptoms versus 43.1% of Nuvaxovid recipients, representing an 18% risk difference. - Nuvaxovid recipients reported less disruption to daily activities including work, school, and recreational activities over seven days following vaccination. - The improved tolerability profile may enhance vaccine confidence and willingness to return for routine COVID-19 immunization, addressing a key barrier to vaccination uptake.
- Oregon Health & Science University secured over $9 million in NIH funding to develop advanced microphysiologic models that recreate how cancers grow, spread and respond to treatment within bone and bone-associated tissues. - Two new projects focus on osteosarcoma, a rare bone cancer affecting children with unchanged survival rates for four decades, and prostate cancer bone metastasis affecting over 80% of advanced patients. - The research utilizes organs-on-chips technology, transparent USB-sized devices containing living human cells that allow real-time observation of cancer behavior at single-cell resolution. - Davies' team will test MCL-1 protein blocking combined with cyclophosphamide chemotherapy, which completely eliminated lung tumors in early lab studies, while Bertassoni's group examines how blood vessel forces and nerve signals influence cancer cell survival in bone.
- Spark Biomedical has initiated the pivotal Phase II LUNA Trial, a randomized, double-blind, sham-controlled study evaluating transcutaneous auricular neurostimulation for reducing heavy menstrual bleeding in 80 participants aged 14-45. - The trial will test whether daily 2-hour sessions of wearable neurostimulation during menstruation can achieve clinically meaningful reductions in menstrual blood loss compared to sham treatment over three treatment cycles. - Heavy menstrual bleeding is one of the most common reasons for gynecologic consultation and a major contributor to iron-deficiency anemia globally, with current treatment options remaining limited for many women. - The study is funded by Wellcome Leap's "The Missed Vital Sign" program, which aims to reduce the time for women to receive effective heavy menstrual bleeding treatment from five years to five months.
- AN2 Therapeutics received FDA clearance to proceed with a 90-patient investigator-initiated trial evaluating epetraborole in patients with Mycobacterium abscessus lung disease. - The multicenter, randomized, double-blind, placebo-controlled study will focus on early-stage, treatment-naïve patients and aims to address the significant unmet need for oral therapies. - Currently, no FDA-approved therapeutics exist for this difficult-to-treat chronic lung infection, with patients relying on complex, off-label intravenous drug regimens. - Patient enrollment is expected to begin in the first quarter of 2026, with the study led by NTM expert Dr. Kevin Winthrop across 10-15 U.S. sites.
- The FDA has approved ferumoxytol (FERABRIGHT™), an iron-based anemia drug, as a contrast agent for brain cancer imaging after nearly three decades of research at Oregon Health & Science University. - The approval provides physicians with a multidimensional imaging tool that can measure tumor blood volume and track immune cells, offering superior visualization compared to traditional gadolinium-based contrast agents. - OHSU partnered with Azurity Pharmaceuticals to conduct phase 3 re-read studies using clinical trial data from nearly two decades to achieve FDA approval through a New Drug Application process. - The breakthrough particularly benefits glioblastoma patients, offering a new approach to imaging assessment that may ultimately improve treatment precision and patient outcomes.
